(396 days)
Not Found
Not Found
No
The document describes reagents for a chemistry analyzer and does not mention any AI or ML components.
No
The device is described as a reagent for quantitative determination, intended for in vitro diagnostic use. It is used in the diagnosis and treatment of diseases but does not actively treat them.
Yes
The document states that the EasyRA reagents are used with the MEDICA "EasyRA Chemistry Analyzer" to measure substances like alkaline phosphatase, aspartate aminotransferase, and amylase. It explicitly mentions that the measurements from these reagents are "used in the diagnosis and treatment of liver, bone, parathyroid and intestinal diseases" and other conditions, which directly indicates a diagnostic purpose. The phrase "For in vitro diagnostic use only" further confirms its diagnostic intent.
No
The device described is a reagent intended for use with a chemistry analyzer, which is a hardware device. The summary focuses on the chemical reagents and their intended use in conjunction with a specific hardware analyzer, not on a standalone software product.
Yes, based on the provided information, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The text explicitly states "For in vitro diagnostic use only" for all three reagents (ALP, AST, and Amylase).
- Purpose: The reagents are intended for the "quantitative determination" of specific substances (enzymes) in human serum and plasma. This is a core function of IVD devices, which are used to examine specimens taken from the human body to provide information for diagnostic purposes.
- Clinical Context: The intended use also mentions that the measurements are used in the "diagnosis and treatment" of various diseases (liver, bone, heart, pancreatic disorders). This further confirms their role in clinical diagnosis.
- Care Setting: The intended user is "clinical laboratories," which is a typical setting for IVD testing.
Therefore, the EasyRA Alkaline phosphatase (ALP), Aspartate Aminotranferase (AST), and Amylase (AMY) reagents, used with the EasyRA Chemistry Analyzer, are clearly intended for in vitro diagnostic purposes.
N/A
Intended Use / Indications for Use
EasyRA Alkaline phosphatase Reagent: The EasyRA Alkaline phosphatase (ALP) reagent is intended for the quantitative determination of alkaline phosphatase in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Measurement of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid and intestinal diseases. For in vitro diagnostic use only.
EasyRA Aspartate Aminotransferase Reagent: The EasyRA Aspartate Aminotranferase (AST) reagent is intended for the quantitative determination of the enzyme Aspartate Aminotranferase in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Measurement of alkaline phosphatase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases. For in vitro diagnostic use only.
EasyRA Amylase Reagent: The EasyRA Amylase (AMY) reagent is intended for the quantitative determination of amylase in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. a-Amylase in serum/plasma is used for the diagnosis and treatment of pancreatitis (inflammation of the pancreas) and other pancreatic disorders. For in vitro diagnostic use only.
Product codes
CJE, CIT, JFJ
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinical laboratories
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1050 Alkaline phosphatase or isoenzymes test system.
(a)
Identification. An alkaline phosphatase or isoenzymes test system is a device intended to measure alkaline phosphatase or its isoenzymes (a group of enzymes with similar biological activity) in serum or plasma. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized depiction of an eagle with outstretched wings, symbolizing protection and care. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the eagle, indicating the department's name and national affiliation.
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
Medica Corporation c/o Dr. Photios Makris Director of Regulatory Affairs 5 Oak Park Drive Bedford, MA 01730
MAY 2 0 2011
K101090 Re:
Trade Name: EasyRA Alkaline Phosphatase Reagent, EasyRA Aspartate Aminotransferase Reagent, EasyRA Amylase Reagent Regulation Number: 21 CFR § 862.1050 Regulation Name: Alkaline phosphatase or isoenzymes test system Regulatory Class: Class II Product Code: CJE, CIT, JFJ Dated: May 11, 2011 Received: May 16, 2011
Dear Dr. Makris:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
1
Page 2 -
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and-Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
CJC.
Courtney Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
:论坛
Enclosure
2
Indication for Use
510(k) Number (if known): K101090
| Device Name:
Indication For Use: | EasyRA Alkaline phosphatase Reagent
The EasyRA Alkaline phosphatase (ALP) reagent is intended for the
quantitative determination of alkaline phosphatase in human serum and
plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical
laboratories. Measurement of alkaline phosphatase or its isoenzymes are
used in the diagnosis and treatment of liver, bone, parathyroid and
intestinal diseases. For in vitro diagnostic use only. |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name:
Indication For Use: | EasyRA Aspartate Aminotransferase Reagent
The EasyRA Aspartate Aminotranferase (AST) reagent is intended for
the quantitative determination of the enzyme Aspartate Aminotranferase
in human serum and plasma, using the MEDICA "EasyRA Chemistry
Analyzer" in clinical laboratories. Measurement of alkaline phosphatase
measurements are used in the diagnosis and treatment of certain types of
liver and heart diseases. For in vitro diagnostic use only. |
| Device Name:
Indication For Use: | EasyRA Amylase Reagent
The EasyRA Amylase (AMY) reagent is intended for the quantitative
determination of amylase in human serum and plasma, using the
MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. a-
Amylase in serum/plasma is used for the diagnosis and treatment of
pancreatitis (inflammation of the pancreas) and other pancreatic
disorders. For in vitro diagnostic use only. |
Prescription Use _ X (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
signature
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K101090